[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 381
6. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S: 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg; 2007 Dec;246(6):932-7; discussion 937-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
  • OBJECTIVE: To assess the reliability of 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) in distinguishing benign from malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and its contribution to surgical decision making.
  • Computed tomography (CT) and magnetic resonance (MR) are unreliable in discriminating a benign from a malignant neoplasm.
  • An adenoma was diagnosed in 13 patients, a borderline tumor in 8, a carcinoma in situ in 5, and an invasive cancer in 21; in 17 patients a tumor sampling was not performed and therefore the histology remained undetermined.
  • Positive criteria of increased uptake on 18-FDG PET was absent in 13 of 13 adenomas and 7 of 8 borderline IPMNs, but was present in 4 of 5 carcinoma in situ (80%) and in 20 of 21 invasive cancers (95%).
  • Furthermore, conventional imaging had findings that would be considered falsely positive in 1 of 13 adenomas (8%) and in 3 of 8 borderline neoplasms (37.5%).
  • CONCLUSIONS: 18-FDG PET is more accurate than conventional imaging techniques (CT and MR) in distinguishing benign from malignant (invasive and noninvasive) IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043094.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Veroux M, Giuffrida G, Gagliano M, Giaquinta A, Tallarita T, Sorbello M, Corona D, Zerbo D, Vizcarra D, Scriffignano V, Cannizzaro MA, Veroux P: Evaluation of thyroid disease in kidney transplantation candidates: management and follow-up. Transplant Proc; 2009 May;41(4):1142-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: One-hundred-four patients with ESRD (44%) had functional or morphologic changes in the thyroid gland.
  • Forty-one patients (17.4%) underwent fine-needle aspiration cytology; 3 demonstrated showed papillary carcinoma; 3, follicular adenomas; 8, uncertain cytologic lesions; and 27, a nodular goiter.
  • Of the 184 transplant recipients, 10 underwent surgery to treat thyroid disease: 8 with multinodular goiter, 1 with micropapillary carcinoma, and 1 with follicular adenoma.
  • [MeSH-major] Carcinoma, Papillary / complications. Kidney Failure, Chronic / surgery. Kidney Transplantation. Neoplasm Recurrence, Local / complications. Thyroid Neoplasms / epidemiology


8. Tabriz HM, Adabi Kh, Lashkari A, Heshmat R, Haghpanah V, Larijani B, Tavangar SM: Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Pract; 2009;205(2):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
  • INTRODUCTION: We aimed at assessing the significance of nm23 gene expression in papillary and follicular carcinomas, the two most common differentiated thyroid carcinomas.
  • MATERIALS AND METHODS: During a cross-sectional study, 173 paraffin blocks, including 131 papillary thyroid carcinomas, 12 follicular carcinomas and 30 follicular adenomas were stained with nm23 marker by immunohistochemistry method.
  • RESULTS: nm23 was positive in 40% of the follicular adenoma, 67.2% of the papillary carcinoma and 66.7% of the follicular carcinoma. p value was more than 0.05 in the assessment of the relationship between nm23 and all of the above-mentioned parameters in differentiated thyroid carcinomas. nm23 expression did not significantly differentiate between follicular adenoma and carcinoma.
  • Also, nm23 cannot be considered as a useful marker for the evaluation of invasion in differentiated thyroid carcinomas or in distinctions between follicular adenoma and carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. NM23 Nucleoside Diphosphate Kinases / biosynthesis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996649.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


9. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer; 2009 Aug 15;125(4):894-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
  • The identification of high-risk patients with thyroid cancer and the preoperative differentiation between follicular adenoma and carcinoma remain clinically challenging.
  • Tumor/normal tissue was collected from 69 prospectively followed patients with thyroid carcinomas (papillary, medullary, follicular and anaplastic, PTC, MTC, FTC and ATC) or follicular adenomas.
  • Carcinomas except MTC expressed significantly more u-PAR/MMPs than adenomas/normal tissues, this being associated with advanced pT- or M-stages.
  • MMP-1 and MMP-9 were significantly higher in follicular carcinomas than in adenomas.
  • This is the first study to suggest MMP-1/-9 as significant differentiation markers between follicular adenoma and follicular carcinoma.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Receptors, Urokinase Plasminogen Activator / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Blotting, Western. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Electrophoretic Mobility Shift Assay. Female. Humans. Immunoenzyme Techniques. Luciferases. Male. Matrix Metalloproteinase 7 / metabolism. Middle Aged. Prognosis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480010.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Urokinase Plasminogen Activator; EC 1.13.12.- / Luciferases; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


10. Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R: Renal oncocytosis and multiple papillary adenomas with oncocytoma as dominant nodule coexisting with papillary carcinoma in a patient with diabetic glomerulosclerosis, acquired renal cystic disease and B cell lymphoma. APMIS; 2008 Oct;116(10):934-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal oncocytosis and multiple papillary adenomas with oncocytoma as dominant nodule coexisting with papillary carcinoma in a patient with diabetic glomerulosclerosis, acquired renal cystic disease and B cell lymphoma.
  • [MeSH-major] Adenoma / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma, Papillary / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis


11. Sancak S, Hardt A, Gärtner R, Eszlinger M, Aslan A, Eren FT, Güllüoglu BM, Sen LS, Sever Z, Akalin NS, Paschke R: Comparison of Color Flow Doppler Sonography (CFDS) and immunohistologic detection of microvessels for the assessment of the malignancy of thyroid nodules. Horm Metab Res; 2010 Aug;42(9):670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The assessment of tumor vascularization by color flow Doppler sonography (CFDS) has been suggested for the distinction between benign and malignant thyroid nodules.
  • Our objective was to investigate if the CFDS results reflect the percentage of histologically determined microvessels in adenomas (As), adenomatous nodules (ANs), and papillary carcinomas (PCs).
  • Tissue sections from 10 adenomas, 8 ANs and 13 PC and surrounding tissue of 10 PCs and 2 benign nodules were immunostained for CD34.
  • We found a consistent percentage increase of CD34 stained microvessels in PCs (83 and 96%) as compared to adenomas and ANs (38 and 49%) determined by the hot spot analysis and systematic field analysis.
  • The analysis of the CFDS-classification IV for the distinction between PCs and adenomas and ANs showed a sensitivity of 62% with a specificity of 100%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20568034.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


12. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, Bartsch DK: Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut; 2009 Oct;58(10):1410-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological examination of the resected specimens showed serous oligocystic adenomas (n = 3), pancreatic intraepithelial neoplasia 1 (PanIN1) lesions with lobular fibrosis (n = 1), PanIN2 lesions (n = 1) and PanIN1 lesion plus a gastric type intraductal papillary mucinous neoplasm (IPMN) (n = 1).


13. Aydin O, Yildiz L, Kefeli M, Kandemir B: CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid. Pathol Res Pract; 2008;204(6):359-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within the neoplastic group, papillary carcinomas differed from follicular adenomas significantly, although papillary carcinomas showed no statistically significant difference compared to follicular carcinomas.
  • The neoplastic group and, within them, the papillary carcinomas showed a higher ratio of CD117 positivity.
  • Although our results need to be confirmed by other molecular and genetic studies, the high rate of positivity in papillary carcinomas was one of the striking findings, which may result in novel diagnostic and therapeutic approaches.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism. Thyroiditis / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337018.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


1
Advertisement
4. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, Iaccarino A, Russo M, Pierantoni GM, Leone V, Sacchetti S, Troncone G, Santoro M, Fusco A: Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res; 2008 Aug 15;68(16):6770-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, it decreased in an increasing percentage of cases going from benign adenomas to papillary (PTC), follicular, and anaplastic (ATC) thyroid carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma / genetics. Carcinoma, Papillary / genetics. Repressor Proteins / genetics. Repressor Proteins / metabolism. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701502.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


15. Hong SP, Lee EK, Park JY, Jeon TJ, Bang S, Park S, Chung JB, Lee WJ, Kim H, Song SY: Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas. Oncol Rep; 2009 Jan;21(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas.
  • However, Cripto-1 expression in intraductal papillary mucinous neoplasms (IPMNs) has yet to be reported.
  • Cripto-1 expression was evaluated by immunohistochemistry using 37 IPMN tissue samples and real-time RT-PCR analysis of seven frozen samples.
  • Cripto-1 was positively stained in 3 of 4 (75%) adenomas, 12 of 19 (63.2%) borderline neoplasms, 5 of 11 (45.5%) non-invasive carcinomas and 2 of 3 (66.7%) invasive carcinomas.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adult. Aged. Female. GPI-Linked Proteins. Gene Expression. Humans. Immunohistochemistry. Intercellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082438.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


16. Okada K, Hirabayashi K, Imaizumi T, Matsuyama M, Yazawa N, Dowaki S, Tobita K, Ohtani Y, Tanaka M, Inokuchi S, Makuuchi H: Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas. Biomed Res; 2010 Feb;31(1):13-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas.
  • The invasion of intraductal papillary-mucinous neoplasm (IPMN) is sometimes difficult to diagnose using only ordinary hematoxylin-eosin sections.
  • The 80 IPMNs were classified into 29 intraductal papillary-mucinous adenomas (IPMAs), 10 borderline IPMNs, 18 noninvasive intraductal papillary-mucinous carcinomas (IPMCs), and 23 invasive IPMCs according to the WHO classification.


17. Rydlova M, Ludvikova M, Stankova I: Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Jun;152(1):53-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty eight thyroid lesions forming four diagnostic groups including adenomatous goiters (AS), follicular adenomas (FA), follicular (FC) and papillary carcinomas (PC) were examined using standard immunohistochemical methods.
  • RESULTS: The cytoplasmatic expression of galectin-3 was positive in all cases of papillary carcinoma.
  • Moreover, statistically significant differences between fused groups of benign (AS and FA) and malignant lesions (FC and PC) were found Fischer's exact test (p = 0.0001).
  • No significant differences in cytoplasmic expression of MMPs -2 and -7 and in vascular density assessed by using of both endothelial markers between benign lesions and malignant tumors were revealed.
  • CONCLUSIONS: Galectin-3 appears to be a useful marker in the diagnosis of papillary carcinoma only.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795075.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


18. Ishida M, Egawa S, Kawaguchi K, Aoki T, Sakata N, Mikami Y, Motoi F, Abe T, Fukuyama S, Katayose Y, Sunamura M, Unno M, Moriya T, Horii A, Furukawa T: Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. Pancreatology; 2008;8(6):577-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas.
  • BACKGROUND/AIMS: Patients with intraductal papillary-mucinous neoplasm (IPMN) of the pancreas are likely to have a better prognosis than those with conventional pancreatic ductal adenocarcinoma.
  • RESULTS: The 61 patients with IPMN in this study comprised 25 with intraductal papillary-mucinous adenomas (IPMA) and 36 with intraductal papillary-mucinous carcinomas (IPMC) including 6 with invasive carcinomas.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 18824881.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Lee SH, Lee DS, You IY, Jeon WJ, Park SM, Youn SJ, Choi JW, Sung R: [Histopathologic analysis of adenoma and adenoma-related lesions of the gallbladder]. Korean J Gastroenterol; 2010 Feb;55(2):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathologic analysis of adenoma and adenoma-related lesions of the gallbladder].
  • BACKGROUND/AIMS: In order to determine the malignant potential of gallbladder adenoma for progression to carcinoma, we evaluated the histopathologic features of adenoma and adenoma-related lesions on cholecystectomized specimens.
  • METHODS: Among 1,847 cholecystectomized specimens, 63 specimens from 26 benign adenomas, 9 carcinomas in situ (CIS), and 28 invasive carcinomas were selected.
  • A pathologist reviewed all specimens and selected benign adenomas, CIS in the adenoma, and adenoma residue in invasive carcinomas.
  • Adenomas and adenoma-related lesions were classified according to morphology (tubular, tubulopapillary, and papillary) and the consisting epithelium (biliary, pyloric metaplasia, and intestinal metaplasia).
  • The age and the size of the benign adenomas and carcinomas in the adenoma were also compared.
  • RESULTS: Adenoma and adenoma-related lesions were found in 34 out (1.8%) of all resected gallbladder.
  • Among 9 CIS and 28 invasive carcinomas, adenoma-related lesions were detected in 7 and 1 case, respectively.
  • All eight carcinomas arising in the adenoma were well-differentiated solitary tumors.
  • The diameters of the carcinomas in the adenoma were, on average, larger than that of the benign adenomas (1.8 cm vs. 0.9 cm, p=0.01).
  • The patients with carcinomas in the adenoma were, on average, older than those with benign adenomas, although the difference was insignificant (57 years vs. 47 years, p=0.09).
  • The morphology and consisting epithelium did not differ between the benign adenomas and carcinomas in the adenoma.
  • The malignant transformation occurred in 23.5% of adenomas.
  • CONCLUSIONS: Gallbladder adenoma is a rare disease, although malignant transformation occurs frequently.
  • Adenoma is a precancerous lesion and the adenoma-carcinoma sequence is one of the gallbladder cancer carcinogenesis.
  • [MeSH-major] Adenoma / pathology. Gallbladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168058.001).
  • [ISSN] 2233-6869
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


20. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A: Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery; 2005 Dec;138(6):1102-9; discussion 1109-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We postulated that expression analysis of genes that modulate angiogenesis would identify differentially expressed genes that would help to distinguish benign from malignant thyroid neoplasms and serve as markers of aggressive differentiated thyroid cancer.
  • METHODS: A complementary DNA (cDNA) array with 96 genes that modulate angiogenesis was used to identify differentially expressed genes (2-fold higher or lower) in malignant versus benign thyroid neoplasms.
  • Real-time quantitative polymerase chain reaction was used to confirm cDNA array expression data in 123 patients (4 normal thyroid, 26 hyperplastic nodules, 27 follicular adenomas, 23 follicular cancers, 18 follicular variant of papillary cancers, 25 papillary cancers).
  • RESULTS: Twenty-two genes were upregulated in malignant thyroid neoplasms by cDNA array analysis, but only 13 genes had higher messenger RNA (mRNA) expression levels in malignant than in benign thyroid neoplasms by real-time quantitative polymerase chain reaction (P < or = .04).
  • Of the 13 differentially expressed genes, the combined use of angiopoietin 2 (ANGPT2) and tissue inhibitor of metalloproteinase 1 (TIMP1) mRNA expression levels was best for distinguishing malignant from benign thyroid neoplasms, with a sensitivity of 90%, specificity of 85%, positive predictive value of 75%, and negative predictive value of 94%.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Angiogenic Proteins / genetics. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics


21. Lü K, Dai Q, Xu ZH, Zhang YX, Tan L, Yuan Y, Jiang YX: Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas. Chin Med Sci J; 2010 Sep;25(3):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas.
  • OBJECTIVE: To analyze the clinical and ultrasonographic imaging features of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • METHODS: Twelve patients with IPMN underwent surgery between May 2005 and December 2008, including 4 (33.3%) with adenoma and 8 (66.7%) with adenocarcinoma.
  • The mean diameters of the lesions were 1.4 +/- 0.8 cm (range, 0.5-2.0) and 6.3 +/- 6.0 cm (range, 2.0-20.0) in adenomas and adenocarcinomas, respectively.
  • And the mean diameters of the main duct in adenomas and adenocarcinomas were 1.0 +/- 0.8 cm and 1.6 +/- 1.0 cm, respectively.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180276.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Ito Y, Motoo Y, Yoshida H, Iovanna JL, Nakamura Y, Kuma K, Miyauchi A: High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid. Pathology; 2006 Dec;38(6):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 39 (20 minimally invasive and 19 widely invasive) follicular carcinomas and 20 adenomas were negative for or expressed only low levels of TP531NP1 except for one widely invasive follicular carcinoma.
  • Of 100 papillary carcinomas, only four (4%) expressed high levels of TP531NP1, and the remaining 96 (96%) were classified into the low group.
  • There were no significant relationships between TP531NP1 expression and clinicopathological features of papillary carcinoma.
  • CONCLUSIONS: These findings suggest that TP531NP1 plays a significant role in the progression of anaplastic carcinoma or contributes to anaplastic transformation from papillary or follicular carcinoma, which is in sharp contrast to findings in previous in vitro and in vivo studies.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Carcinoma, Papillary / pathology. Carcinoma, Papillary, Follicular / metabolism. Carcinoma, Papillary, Follicular / pathology. Gene Expression Regulation, Neoplastic. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393983.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Heat-Shock Proteins; 0 / TP53INP1 protein, human
  •  go-up   go-down


23. Morris-Stiff GJ, Senda Y, Verbeke CS, Lodge PA: Papillary adenoma arising in the left hepatic duct: an unusual tumour in an uncommon location. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):886-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma arising in the left hepatic duct: an unusual tumour in an uncommon location.
  • Bile duct adenomas are rare tumours that arise more frequently in the distal extrahepatic biliary tree.
  • We report the case of a papillary adenoma arising at the junction of the common and left hepatic ducts and review the available literature on this rare entity.
  • At laparotomy, there was no evidence of extraductal tumour, and choledochoscopy showed a papillary lesion within the common hepatic and proximal left hepatic ducts.
  • Histological evaluation of the resected specimen confirmed a papillary adenoma with mild dysplasia.
  • [MeSH-major] Adenoma / diagnosis. Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for papillary adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545030.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.3.2.2 / gamma-Glutamyltransferase
  • [Number-of-references] 10
  •  go-up   go-down


24. Patek CE, Arends MJ, Wallace WA, Luo F, Hagan S, Brownstein DG, Rose L, Devenney PS, Walker M, Plowman SJ, Berry RL, Kolch W, Sansom OJ, Harrison DJ, Hooper ML: Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp Cell Res; 2008 Mar 10;314(5):1105-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung tumours in all genotypes were predominantly papillary adenomas, and tumours from K-ras(+/-) and K-ras(tmDelta4A/-) mice exhibited phospho-Erk1/2 and phospho-Akt staining.


25. Bussom S, Saif MW: Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP; 2010;11(2):131-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
  • The diagnosis and treatment of intraductal papillary mucinous tumors (IPMN) of the pancreas has evolved over the last decade.
  • IPMN is a disease of the ductal epithelium and represent a spectrum of disease, ranging from benign to malignant lesions, making the early detection and characterization of these lesions important.
  • As with villous adenomas of the colon, not all IPMNs will develop into adenocarcinoma.
  • Definitive management is surgical resection for appropriate candidates, as benign lesions harbor malignant potential.
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Congresses as Topic. Cyst Fluid / chemistry. Cytokines / analysis. Early Detection of Cancer / methods. Enzyme-Linked Immunosorbent Assay. Gastrointestinal Neoplasms / diagnosis. Humans. Models, Biological. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208320.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 26
  •  go-up   go-down


26. Sheu SY, Handke S, Bröcker-Preuss M, Görges R, Frey UH, Ensinger C, Ofner D, Farid NR, Siffert W, Schmid KW: The C allele of the GNB3 C825T polymorphism of the G protein beta3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours. J Pathol; 2007 Jan;211(1):60-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carriers of the C allele of the common C825T polymorphism in the GNB3 gene of the G protein have been associated with the development of follicular thyroid adenomas.
  • Using pyrosequencing, both the genotype distribution and the allele frequency of the C825T polymorphism were investigated in a series of 104 patients with oncocytic thyroid tumours of follicular cell origin [58 adenomas, 41 follicular thyroid carcinomas (FTCs), and five papillary thyroid carcinomas (PTCs)]; the results were compared with those obtained from 321 age and gender-matched healthy blood donors and a series of 327 non-oncocytic thyroid tumours of follicular cell origin (119 adenomas, 80 FTCs, and 186 PTCs).
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Heterotrimeric GTP-Binding Proteins / genetics. Polymorphism, Genetic. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Alleles. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. Case-Control Studies. Female. Gene Frequency. Genotype. Humans. Male. Middle Aged. Mitochondria / metabolism. Odds Ratio. Risk. Thyroid Hormones / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 17136758.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / G-protein beta3 subunit; 0 / Thyroid Hormones; EC 3.6.5.1 / Heterotrimeric GTP-Binding Proteins
  •  go-up   go-down


27. Almeida JP, Couto Netto SD, Rocha RP, Pfuetzenreiter EG Jr, Dedivitis RA: The role of intraoperative frozen sections for thyroid nodules. Braz J Otorhinolaryngol; 2009 Mar-Apr;75(2):256-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They underwent intraoperative FS evaluation, and the biopsy material was classified as benign, malignant or follicular neoplasm.
  • RESULTS: Under the FS, 54% of the nodules were benign, 30% were follicular neoplasms, and 16% were malignant.
  • All cases considered benign and malignant under the FS evaluation were confirmed through the histological 'paraffin' analysis.
  • Since it is not considered a definitive indication for total thyroidectomy, if the follicular neoplasms were classified as 'benign' under the FS, their sensitivity, specificity, positive and negative predictive values and global diagnostic accuracy were 69%, 100%, 100%, 91,5% e 77%, respectively.
  • Among the 42 cases classified as 'follicular neoplasm' under the FNAB, in 1 case the FS conclusion was for papillary carcinoma, in 3 cases as benign (all confirmed through the 'paraffin'); and 38 cases continued as 'follicular pattern', being 29 follicular adenomas and 9 carcinomas through the 'paraffin'.
  • [MeSH-major] Biopsy, Fine-Needle / standards. Carcinoma, Papillary / pathology. Frozen Sections. Lymph Nodes / pathology. Thyroid Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575113.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


28. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Dante R, Rousset B: Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab; 2005 May;90(5):3028-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas.
  • SLC5A8 expression, unlike that of SLC5A5 and SLC26A4, was not regulated by TSH in normal human thyrocytes in culture and was not related to the functional state of thyroid tissue; toxic adenomas and adjacent resting tissues exhibited the same SLC5A8 transcript content.
  • SLC5A8 expression was selectively down-regulated (40-fold) in papillary thyroid carcinomas of classical form (PTC-cf.).
  • Methylation-specific PCR analyses showed that SLC5A8 was methylated in 90% of PTC-cf. and in about 20% of other papillary thyroid carcinomas.
  • [MeSH-major] Carcinoma, Papillary / genetics. Cation Transport Proteins / genetics. Gene Silencing. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15687339.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 2; 0 / Cation Transport Proteins; 0 / Membrane Transport Proteins; 0 / SLC26A4 protein, human; 0 / SLC5A8 protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


29. Arora N, Scognamiglio T, Lubitz CC, Moo TA, Kato MA, Zhu B, Zarnegar R, Chen YT, Fahey TJ 3rd: Identification of borderline thyroid tumors by gene expression array analysis. Cancer; 2009 Dec 1;115(23):5421-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A subset of follicular lesions of the thyroid is encapsulated similar to follicular adenomas but with partial nuclear features suggestive of papillary thyroid carcinoma (PTC), raising the possibility of biologically borderline tumors.
  • METHODS: Gene expression profiling and advanced significance analyses were performed on 50 histologically unequivocal benign and malignant tumors, and a list of 61 differentially expressed genes was generated.
  • By using this 61-gene list, unsupervised hierarchical and K-means cluster analyses were performed on 40 additional tumors, including 15 histologically borderline tumors, 11 benign tumors, and 14 PTCs.
  • RESULTS: Analysis revealed 3 distinct tumor groups-benign, malignant, and intermediate.
  • Tumors in the intermediate group (n = 15) were mostly histologic borderline tumors and had an expression profile overlapping with the benign and malignant groups.
  • Twenty-seven genes were expressed differentially between the benign and intermediate groups, including the cyclic AMP response element-binding protein/p300-interactivator with glutamic acid/aspartic acid-rich carboxy-terminal domain 1 or CITED1 gene and the fibroblast growth factor receptor 2 or FGFR2 gene.
  • Mutations of the v-raf murine sarcoma viral oncogene homolog B1 or BRAF gene were identified in 4 of 14 malignant tumors but not in benign or intermediate tumors.
  • CONCLUSIONS: Gene expression profiling supported the finding that encapsulated thyroid follicular lesions with partial nuclear features of PTC are biologically borderline tumors that are distinct molecularly from benign and malignant tumors.
  • [MeSH-minor] Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / genetics. Cluster Analysis. Follow-Up Studies. Humans. Mutation. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins B-raf / genetics


30. Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A, Frangou-Lazaridis M: Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers? Neoplasma; 2007;54(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?
  • Genetic analysis of the aspirates by RT-PCR may contribute, in parallel to the cytology report, to a more precise diagnosis.
  • A semi-quantitative RT-PCR assay was developed to determine prothymosin alpha and parathymosin mRNA expression patterns in thyroid follicular cells obtained from the fine-needle aspiration biopsy specimens of patients diagnosed with simple nodular goitre, follicular adenoma, papillary and follicular well-differentiated carcinomas.
  • Prothymosin alpha and parathymosin mRNA levels were found significantly elevated in well-differentiated carcinomas in relation to adenomas (p<0.05) and goitres (p<0.05), an event possibly linked to the proliferation activity of thyroid follicular cells.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adult. Aged. Biomarkers / analysis. Biopsy, Fine-Needle / methods. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Nodule / genetics. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203893.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / prothymosin alpha; 61512-21-8 / Thymosin; 95328-48-6 / parathymosin alpha
  •  go-up   go-down


31. Roberts SS, Mendonça-Torres MC, Jensen K, Francis GL, Vasko V: GABA receptor expression in benign and malignant thyroid tumors. Pathol Oncol Res; 2009 Dec;15(4):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GABA receptor expression in benign and malignant thyroid tumors.
  • We examined the expression patterns of the GABAergic system in 70 human thyroid tumor samples (13 follicular adenomas, 14 follicular carcinomas, 43 papillary carcinomas) and adjacent normal thyroid by immunohistochemistry.
  • Expression levels of GABAB R2 and GABA receptor associated protein (GABARAP) are increased in adenomas and thyroid cancer suggesting their role in early stages of thyroid tumorigenesis.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. Microtubule-Associated Proteins / metabolism. Receptors, GABA-A / metabolism. Receptors, GABA-B / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2006 Jul;144(3):332-44 [16527506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2803-8 [17296934.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):383-90 [11144533.001]
  • [Cites] Psychoneuroendocrinology. 1987;12(1):53-9 [2884685.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):69-80 [18221027.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):61-6 [7279009.001]
  • [Cites] Endocr Dev. 2007;10:140-72 [17684395.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Cell Tissue Res. 1981;220(4):873-9 [7296659.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2270-82 [11948410.001]
  • [Cites] Life Sci. 1990;46(21):1489-501 [2162457.001]
  • [Cites] Annu Rev Neurosci. 1994;17:569-602 [7516126.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51841-50 [14530254.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):27-30 [11121859.001]
  • [Cites] Prog Exp Tumor Res. 2007;39:91-8 [17314503.001]
  • [Cites] Med Hypotheses. 2006;67(1):33-5 [16516401.001]
  • [Cites] Thyroidology. 1989 Dec;1(3):105-8 [2484871.001]
  • [Cites] J Physiol Pharmacol. 1998 Jun;49(2):303-10 [9670113.001]
  • [Cites] Neuroscience. 1996 Aug;73(3):705-13 [8809792.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):414-24 [2380337.001]
  • [Cites] Med Sci Monit. 2001 May-Jun;7(3):377-81 [11386012.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Jun;18(2):247-53 [10464715.001]
  • [Cites] Neurosci Res. 1999 Nov;35(2):145-53 [10616918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18 [15325588.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3017-24 [16303767.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):97-116 [15027888.001]
  • (PMID = 19381877.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GABARAP protein, human; 0 / Microtubule-Associated Proteins; 0 / Receptors, GABA; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B
  •  go-up   go-down


32. Mönkemüller K, Fry LC, Ebert M, Bellutti M, Venerito M, Knippig C, Rickes S, Muschke P, Röcken C, Malfertheiner P: Feasibility of double-balloon enteroscopy-assisted chromoendoscopy of the small bowel in patients with familial adenomatous polyposis. Endoscopy; 2007 Jan;39(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small-bowel polyps (including papillary adenomas) were detected in seven patients (88 %).
  • In one patient the polyps were flat and only visible with chromoendoscopy (biopsy confirmed these to be adenomas).
  • [MeSH-minor] Adenoma. Adolescent. Adult. Feasibility Studies. Female. Humans. Male. Middle Aged. Prospective Studies


33. Banito A, Pinto AE, Espadinha C, Marques AR, Leite V: Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf); 2007 Nov;67(5):706-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Ploidy status was determined by flow cytometry in 111 thyroid lesions (42 follicular thyroid adenomas, 27 follicular thyroid carcinomas, 19 follicular variants of papillary thyroid carcinoma, 20 poorly differentiated thyroid carcinomas and 3 anaplastic thyroid carcinomas).
  • The aneuploid tumours harbouring RAS mutations were two poorly differentiated carcinomas and one follicular variant of papillary thyroid carcinoma with poorly differentiated areas.
  • Three of five (60%) follicular thyroid adenomas and 1 of 7 (14%) follicular thyroid carcinomas, with the PAX8/PPARgamma fusion gene, were aneuploid.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Aneuploidy. Genes, ras. Point Mutation. Thyroid Neoplasms / genetics
  • [MeSH-minor] Carcinoma / genetics. Carcinoma, Papillary, Follicular / genetics. DNA Mutational Analysis. Flow Cytometry. Gene Rearrangement. Humans. Oncogene Proteins, Fusion. PPAR gamma / genetics. Paired Box Transcription Factors / genetics. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651453.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  •  go-up   go-down


34. Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, Cozzolino M, Keller S, Fedele M, Leone V, Troncone G, Chiariotti L, Pucci P, Fusco A: Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res; 2009 Sep 1;69(17):7079-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, CBX7 protein levels decreased in an increasing percentage of cases going from benign adenomas to papillary, follicular, and anaplastic thyroid carcinomas.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Papillary / metabolism. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Repressor Proteins / biosynthesis. Repressor Proteins / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706751.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cadherins; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Repressor Proteins; EC 3.5.1.98 / Hdac2 protein, rat; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


35. Joseph B, Ji M, Liu D, Hou P, Xing M: Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab; 2007 Dec;92(12):4766-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We found no TRalpha gene mutation in 17 papillary thyroid cancers (PTCs) and 11 follicular thyroid cancers (FTCs), and no TRbeta gene mutation in 16 PTCs and 12 FTCs.
  • We also found no methylation of the TRalpha gene in 33 PTCs, 31 FTCs, 20 follicular thyroid adenomas (FTAs), and 10 thyroid tumor cell lines.
  • In contrast, we found hypermethylation of the TRbeta gene in 10 of 29 (34%) PTCs, 22 of 27 (81%) FTCs, five of 20 (25%) follicular thyroid adenomas, and three of 10 (30%) thyroid tumor cell lines, with the highest prevalence in FTC.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Thyroid Hormone Receptors alpha / genetics. Thyroid Hormone Receptors beta / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17911173.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Thyroid Hormone Receptors alpha; 0 / Thyroid Hormone Receptors beta
  •  go-up   go-down


36. Krzeslak A, Gaj Z, Pomorski L, Lipinska A: Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis. Mol Med Rep; 2008 Jul-Aug;1(4):565-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of several studies suggest that CK19 may be useful in the diagnosis of papillary carcinoma, where it has been shown to have strong diffuse cytoplasmic reactivity.
  • The aim of this study was to evaluate, by Western blot analysis and the enzyme-linked immunosorbent assay (ELISA), the expression of CK19 in the cytosolic fraction obtained from 125 specimens of various thyroid lesions: nodular goiters, follicular adenomas, papillary carcinomas, follicular carcinomas and anaplastic carcinomas.
  • The analysis of CK19 expression using the ELISA showed that the majority of papillary carcinoma cases had a much higher level of CK19 than did nodular goiters and adenomas (P<0.001).
  • Western blot analysis revealed the presence of CK19 in 66% of papillary carcinoma cases.
  • CK19 expression was also found in 11, 22, 25 and 25% of nodular goiters, follicular adenomas, and follicular and anaplastic carcinomas, respectively.
  • The results demonstrate that the evaluation of CK19 expression may be helpful in distinguishing papillary carcinoma from other benign and malignant thyroid nodules, but cannot by itself be used to establish a diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479451.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


37. Sheu SY, Grabellus F, Schwertheim S, Worm K, Broecker-Preuss M, Schmid KW: Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer; 2010 Jan 19;102(2):376-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours.
  • BACKGROUND: Recent studies showed a significant upregulation of distinct microRNAs (miRNAs) in papillary thyroid carcinoma (PTC).
  • METHODS: We used total RNA of 113 formalin-fixed paraffin-embedded tissues of 50 PTCs ((10 conventional type (PTC-CT), 10 tall cell variants (PTC-TCVs), 30 follicular variants (PTC-FVs)), 10 follicular adenomas (FAs), 10 multinodular goitres (MNGs), 21 follicular thyroid carcinomas and 22 well-differentiated tumours of unknown malignant potential (WDT-UMP) to analyse the miRNA expression pattern of five selected miRNAs (146b, 181b, 21, 221 and 222) using RT-PCR TaqMan miRNA assay to explore the diagnostic utility of this method.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. MicroRNAs / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adult. Aged. Female. Gene Expression Profiling. Goiter, Nodular / genetics. Goiter, Nodular / pathology. Humans. Male. Middle Aged. Thyroid Diseases / genetics. Thyroid Diseases / pathology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):475-81 [19370508.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Ann Surg. 1953 Jul;138(1):33-8 [13058300.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):589-95 [15902486.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2537-45 [16331254.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):279-83 [16627915.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):497-508 [16728577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6 [16885212.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91 [16822819.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):779-87 [17464312.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2007 Jul;51(5):843-51 [17891249.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90 [17785355.001]
  • [Cites] APMIS. 2007 Oct;115(10):1090-106 [18042145.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7590-5 [17563749.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):163-73 [18058265.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1600-8 [18270258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 20;105(20):7269-74 [18474871.001]
  • [Cites] Mod Pathol. 2008 Sep;21(9):1139-46 [18587330.001]
  • [Cites] Oncogene. 2009 Jan 8;28(1):73-84 [18850008.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):482-7 [19370505.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):279-87 [15505528.001]
  • (PMID = 20029416.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2816660
  •  go-up   go-down


38. Ozolins A, Narbuts Z, Strumfa I, Volanska G, Gardovskis J: Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg; 2010 Sep;395(7):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: For management of thyroid nodules, distinction between benign and malignant tumours is essential.
  • MATERIALS AND METHODS: Immunohistochemistry for CD56, HBME-1, COX-2, Ki-67, p53 and E-cadherin (E-CAD) was performed in 113 benign and 35 malignant thyroid lesions including 36 follicular adenomas (FA), 77 colloid goitres, 26 papillary thyroid carcinomas (PTC) and 9 follicular carcinomas (FC).
  • RESULTS: PTC was characterised by decreased E-CAD and CD56 expression in contrast to surrounding benign thyroid tissues.
  • HBME-1 expression was absent in benign thyroid tissues but was notably high in PTC and occasionally in FC.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1997 Jan 6;70(1):32-8 [8985087.001]
  • [Cites] Endocr J. 2003 Apr;50(2):173-7 [12803237.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1643-54 [8635070.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jun;129(6):736-41 [15913419.001]
  • [Cites] Eur J Endocrinol. 2008 Mar;158(3):375-84 [18299472.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):179-82 [15816536.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jan;60(1):18-20 [14678282.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Folia Histochem Cytobiol. 2008;46(4):461-4 [19141399.001]
  • [Cites] Surg Today. 1995;25(3):217-21 [7640449.001]
  • [Cites] Diagn Pathol. 2008 Feb 06;3:5 [18254952.001]
  • [Cites] Am J Forensic Med Pathol. 2009 Mar;30(1):78-83 [19237863.001]
  • [Cites] Diagn Cytopathol. 2008 Aug;36(8):550-6 [18618720.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4987-93 [8402689.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1631-7 [16998461.001]
  • [Cites] Genes Dev. 1991 Feb;5(2):151-9 [1995413.001]
  • [Cites] Clin Exp Immunol. 1992 Sep;89(3):474-8 [1381304.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2672-7 [16670159.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1083-93 [2525423.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):375-81 [7684202.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Int J Surg Pathol. 2001 Oct;9(4):265-72 [12574841.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] J Korean Med Sci. 2005 Oct;20(5):853-9 [16224162.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):358-63 [11788675.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):818-23 [18212751.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] Diagn Pathol. 2010 Jan 26;5:9 [20181018.001]
  • [Cites] Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi [17673125.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] Lijec Vjesn. 2006 Sep-Oct;128(9-10):264-7 [17128663.001]
  • [Cites] World J Surg. 2008 Dec;32(12):2617-22 [18836853.001]
  • [Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] J Pathol. 2007 Aug;212(4):411-9 [17573672.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2501-7 [9192832.001]
  • [Cites] Endocr Pathol. 2004 Summer;15(2):107-16 [15299197.001]
  • [Cites] Int J Oncol. 1999 Nov;15(5):893-8 [10536170.001]
  • [Cites] Am J Pathol. 1989 Jul;135(1):101-10 [2774055.001]
  • [Cites] Histopathology. 2002 Feb;40(2):133-42 [11952857.001]
  • [Cites] Ann Clin Lab Sci. 2000 Jan;30(1):3-21 [10678579.001]
  • [Cites] J Surg Oncol. 2006 Dec 15;94(8):662-9 [17131411.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Mar;56(3):281-90 [11940037.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Cytojournal. 2009 Sep 18;6:18 [19826479.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):107-16 [1740296.001]
  • [Cites] J Korean Med Sci. 2007 Aug;22(4):621-8 [17728499.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • (PMID = 20640858.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / HBME-1 antigen; 0 / Ki-67 Antigen; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


39. Carling T, Udelsman R: Follicular neoplasms of the thyroid: what to recommend. Thyroid; 2005 Jun;15(6):583-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An FNA diagnosis of a follicular neoplasm represents a heterogeneous group of lesions including benign follicular hyperplasia, follicular adenomas, follicular carcinomas, and the follicular variant of papillary carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029125.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


40. Dietrich CF, Ignee A, Braden B, Barreiros AP, Ott M, Hocke M: Improved differentiation of pancreatic tumors using contrast-enhanced endoscopic ultrasound. Clin Gastroenterol Hepatol; 2008 May;6(5):590-597.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All other pancreatic lesions revealed an isovascular or hypervascular pattern using contrast-enhanced endoscopic ultrasound (20 neuroendocrine tumors, 10 serous microcystic adenomas, and 1 teratoma).
  • [MeSH-major] Adenocarcinoma, Papillary / ultrasonography. Carcinoma, Pancreatic Ductal / ultrasonography. Contrast Media. Endosonography / methods. Image Enhancement. Pancreatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2008 Dec;5(12):662-3 [18852727.001]
  • (PMID = 18455699.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


41. Gupta R, Mortelé KJ, Tatli S, Girshman J, Glickman JN, Levy AD, Erturk SM, Heffess CS, Banks PA, Silverman SG: Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes. AJR Am J Roentgenol; 2008 Nov;191(5):1458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes.
  • OBJECTIVE: The objective of our study was to evaluate whether CT can be used to predict the pathologic subtypes of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
  • MATERIALS AND METHODS: Three radiologists, blinded to the pathologic IPMN subtype, retrospectively and independently reviewed the preoperative CT scans of 38 patients with surgically resected pancreatic IPMN: 11 intraductal papillary mucinous adenomas, 11 intraductal papillary mucinous carcinomas, and 16 intraductal papillary mucinous carcinomas with invasion.
  • RESULTS: Predominant main pancreatic duct (MPD) involvement (p = 0.04) and a wide (> 1 cm) connection of a side-branch lesion with the MPD (p = 0.03) correlated with intraductal papillary mucinous carcinoma with invasion.
  • Tumor size, MPD diameter, number of tumors per patient, number of pseudoseptations per tumor, common bile duct dilatation, enlarged lymph nodes, intraductal calcifications, papillary bulging, and presence and size of a solid mass yielded no statistically significant relationship with pathologic subtype.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] AJR Am J Roentgenol. 2008 Dec;191(6):1876
  • (PMID = 18941085.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Schittenhelm J, Psaras T, Meyermann R, Honegger J, Beschorner R: Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. Folia Neuropathol; 2010;48(2):75-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.
  • OBJECTIVES: Previous studies have shown an inverse correlation between the expression of CDX2 (also known as CDX3) and tumour grade, stage and lymph node dissemination in colorectal adenomas and adenocarcinomas.
  • Furthermore, only very few data are available on CDX2 expression in normal pituitary gland tissue and/or pituitary adenomas.
  • MATERIAL AND METHODS: We investigated CDX2 expression in 28 normal pituitary glands, 75 pituitary adenomas of varying hormonal activity (including 7 invasive adenomas and 7 atypical adenomas) and 23 craniopharyngiomas (17 adamantinous and 6 papillary) in tissue microarrays.
  • RESULTS: None of the pituitary adenomas, craniopharyngiomas and normal pituitary glands showed expression of CDX2.
  • CONCLUSIONS: There is no evidence for that CDX2 might play a role in tumourigenesis, invasive growth or tumour recurrence of pituitary adenomas or in tumourigenesis of craniopharyngiomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602288.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


43. Vassiliou I, Kairi-Vassilatou E, Marinis A, Theodosopoulos T, Arkadopoulos N, Smyrniotis V: Malignant potential of intrahepatic biliary papillomatosis: a case report and review of the literature. World J Surg Oncol; 2006;4:71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is characterized by multiple papillary adenomas involving both the intrahepatic and extrahepatic biliary tree.
  • CONCLUSION: BP should not be considered to be a benign disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2005 Feb;20(2):321-4 [15683443.001]
  • [Cites] Surg Today. 2003;33(10):781-4 [14513330.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(5):390-5 [14598142.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):783-93 [14770435.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1074-8 [8903378.001]
  • [Cites] Gastrointest Endosc. 1998 Jun;47(6):563-4 [9647397.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1347-55 [10573510.001]
  • [Cites] Diagn Cytopathol. 2000 May;22(5):293-8 [10790236.001]
  • [Cites] Liver Transpl. 2001 Mar;7(3):264-6 [11244169.001]
  • [Cites] Histopathology. 2001 Jun;38(6):550-60 [11422499.001]
  • [Cites] J Hepatol. 2001 Oct;35(4):542-3 [11682045.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):369-71 [11860318.001]
  • [Cites] Hum Pathol. 2002 May;33(5):503-11 [12094375.001]
  • [Cites] Surg Today. 2002;32(11):1019-22 [12444445.001]
  • [Cites] J Comput Assist Tomogr. 2002 Nov-Dec;26(6):968-74 [12488745.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):731-3 [16341314.001]
  • [Cites] Gut. 1990 May;31(5):558-60 [2190867.001]
  • [Cites] Int J Cancer. 1993 Aug 19;55(1):82-91 [8393843.001]
  • (PMID = 17026772.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1618388
  •  go-up   go-down


44. Sak SD, Koseoglu RD, Demirag F, Akbulut H, Gungor A: Alveolar adenoma of the lung. Immunohistochemical and flow cytometric characteristics of two new cases and a review of the literature. APMIS; 2007 Dec;115(12):1443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar adenoma of the lung. Immunohistochemical and flow cytometric characteristics of two new cases and a review of the literature.
  • Alveolar adenoma is a rare and benign tumour of the lung that usually presents in asymptomatic patients as a coin lesion on chest radiography.
  • Alveolar adenoma has a characteristic multicystic histology and often resembles the normal lung parenchyma.
  • Immunohistochemical analysis may aid in the characterization of alveolar adenoma and discriminate this condition from other types of benign lesions of the lung.
  • An indolent clinical progression and absence of recurrence and metastasis after complete resection are the most important characteristics indicative of the benign nature of alveolar adenoma.
  • Few studies have been conducted at the molecular level, such as by flow cytometry, with the objective of characterizing the biological nature of alveolar adenoma.
  • Differential diagnoses include sclerosing hemangioma, papillary adenoma, lymphangioma, atypical adenomatous hyperplasia and bronchioloalveolar carcinoma.
  • [MeSH-major] Adenoma / pathology. Pulmonary Alveoli / pathology. Solitary Pulmonary Nodule / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184418.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


45. Isenmann R, Henne-Bruns D: [Indications for surgical resection of benign pancreatic tumors]. Radiologe; 2008 Aug;48(8):732; 734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indications for surgical resection of benign pancreatic tumors].
  • Benign pancreatic tumors should undergo surgical resection when they are symptomatic or--in the case of incidental discovery--bear malignant potential.
  • This is the case for the majority of benign pancreatic tumors, especially for intraductal papillary mucinous neoplasms or mucinous cystic adenomas.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] Arch Surg. 2008 Mar;143(3):289-95; discussion 295 [18347277.001]
  • [Cites] Ann Surg. 1989 Mar;209(3):273-8 [2923514.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2339-49 [17764489.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] World J Surg. 2008 May;32(5):904-17 [18264824.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] World J Surg. 2003 Nov;27(11):1249-57 [14502404.001]
  • [Cites] Chirurg. 2007 Aug;78(8):713-20 [17628760.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):61-70 [16794390.001]
  • [Cites] Langenbecks Arch Surg. 2000 Apr;385(3):229-33 [10857496.001]
  • [Cites] Ann Surg. 1994 Oct;220(4):492-504; discussion 504-7 [7524454.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] Z Gastroenterol. 2007 Jun;45(6):487-523 [17607616.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):69-76 [17592293.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):155-78 [16517154.001]
  • [Cites] Langenbecks Arch Surg. 2006 Jun;391(3):195-202 [16491403.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] Br J Surg. 2008 Jan;95(1):85-91 [18041022.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):846-50 [12828102.001]
  • [Cites] Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70 [16924083.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):681-6 [16739338.001]
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):855-66 [9684147.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • (PMID = 18560798.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


46. Nguyen HD, Galitz MS, Mai VQ, Clyde PW, Glister BC, Shakir MK: Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge. Thyroid; 2010 Jan;20(1):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
  • BACKGROUND: A thyrotropin (TSH)-secreting pituitary adenoma coexisting with differentiated thyroid carcinoma is rare.
  • METHODS: We hereby report the fifth case, in which a patient presented with a TSH/growth-hormone-secreting pituitary macroadenoma coexisting with papillary thyroid carcinoma (PTC).
  • She has remained asymptomatic for 24 months without biochemical or radiological evidence of pituitary hormone oversecretion, pituitary adenoma enlargement, and PTC recurrence.
  • [MeSH-major] Adenoma. Carcinoma, Papillary. Human Growth Hormone / biosynthesis. Neoplasms, Multiple Primary. Pituitary Neoplasms. Thyroid Neoplasms. Thyrotropin / biosynthesis

  • Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067380.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


47. Rautou PE, Lévy P, Vullierme MP, O'Toole D, Couvelard A, Cazals-Hatem D, Palazzo L, Aubert A, Sauvanet A, Hammel P, Hentic O, Rebours V, Pelletier AL, Maire F, Ruszniewski P: Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol; 2008 Jul;6(7):807-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study.
  • BACKGROUND & AIMS: Because there is a low risk of malignancy for intraductal papillary and mucinous neoplasms of the pancreas (IPMNs) confined to branch ducts (BD), patient follow-up evaluation without surgery is possible.
  • The aim of this study was to assess time-related morphologic changes and risk of progress to malignancy in patients with BD IPMN.
  • After a median follow-up period of 33 months, no morphologic changes had occurred in 88 patients.
  • Surgery, performed in 8 of 12 patients, found 4 IPMN-adenomas, 1 borderline-IPMN, and 4 IPMN carcinoma in situ.
  • CONCLUSIONS: In patients with IPMNs confined to BD, morphologic changes are rare events, justifying a nonsurgical approach.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2008 Jul;6(7):724-5 [18602034.001]
  • (PMID = 18304885.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Durand S, Ferraro-Peyret C, Selmi-Ruby S, Paulin C, El Atifi M, Berger F, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Rousset B: Evaluation of gene expression profiles in thyroid nodule biopsy material to diagnose thyroid cancer. J Clin Endocrinol Metab; 2008 Apr;93(4):1195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Detection of thyroid cancer among benign nodules on fine-needle aspiration biopsies (FNAB), which presently relies on cytological examination, is expected to be improved by new diagnostic tests set up from genomic data.
  • OBJECTIVE: The aim of the study was to use a set of genes discriminating benign from malignant tumors, on the basis of their expression levels, to build tumor classifiers and evaluate their capacity to predict malignancy on FNAB.
  • DESIGN: We analyzed the level of expression of 200 potentially informative genes in 56 thyroid tissue samples (benign or malignant tumors and paired normal tissue) using nylon macroarrays.
  • RESULTS: A series of 19 genes with a similar expression in follicular adenomas and normal tissue and discriminating follicular adenomas+normal tissue from the following:.
  • 1) follicular thyroid carcinomas (FTCs), 2) papillary thyroid carcinomas (PTCs), or 3) both FTCs and PTCs.
  • CONCLUSIONS: We developed a procedure of molecular diagnosis of benign vs. malignant tumors applicable to the material collected by FNAB.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211972.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Fu Q, Yao GY, Tang XL, Chen LR, Zheng ZX: [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions]. Zhonghua Zhong Liu Za Zhi; 2007 Jan;29(1):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the incidence and clinicopathologic significance of MSI and LOH on 3P in breast carcinoma and its precancerous lesions, intraductal papillary adenoma and ductal carcinoma in situ.
  • METHODS: 41 paired sporadic invasive breast carcinomas, 13 archival precancerous lesion specimens of the breast and 14 couples of benign hyperplasia were collected.
  • There was no MSI in benign hyperplasia.
  • [MeSH-minor] Acid Anhydride Hydrolases / metabolism. Adaptor Proteins, Signal Transducing / metabolism. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. DNA Mismatch Repair. Female. Humans. Hyperplasia. Immunohistochemistry. Loss of Heterozygosity. Lymphatic Metastasis. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Nuclear Proteins / metabolism. Polymerase Chain Reaction. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575691.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


50. Zhu XL, Zhou XY, Zhang TM, Zhu XZ: [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation]. Zhonghua Bing Li Xue Za Zhi; 2006 Feb;35(2):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
  • OBJECTIVE: To evaluate the expressions of wildtype-RET (WT-RET) and RET/PTC in sporadic adult papillary thyroid carcinoma and to investigate their clinicopathologic correlation.
  • METHODS: Sixty-six papillary thyroid carcinomas (PTC) and thirty-six control cases with frozen and paraffin-embedded tissues were analyzed for the expressions of WT-RET and oncogene RET/PTC1 or RET/PTC3 by nested RT-PCR. RESULTS:.
  • One of eight adenomas (12.5 %) expressed wild-type RET (WT-RET). (3) Fourteen PTCs (21.2%) expressed RET/PTC, including five cases expressing RET/PTC1 and nine cases expressing RET/PTC3.
  • The expression patterns of WT-RET in PTC and adenoma suggest that there are different molecular mechanisms in activating RET proto-oncogene in thyroid tumors.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Gene Rearrangement. Oncogene Proteins, Fusion / biosynthesis. Protein-Tyrosine Kinases / biosynthesis. Proto-Oncogene Proteins c-ret / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adolescent. Adult. Aged. Female. Hashimoto Disease / metabolism. Humans. Lymphatic Metastasis. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630482.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human
  •  go-up   go-down


51. Camargo RS, Shirata NK, di Loreto C, Garcia EA, Castelo A, Longatto Filho A: Significance of AgNOR measurement in thyroid lesions. Anal Quant Cytol Histol; 2006 Aug;28(4):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases studied included 3 goiters, 10 follicular adenomas, 6 Hürthle adenomas, 4 follicular carcinomas, 7 papillary carcinomas, and 3 Hürthle carcinomas.
  • For statistical purposes, lesions were classified as benign and malignant, and both the number and the area of counted NORs showed very similar values.
  • The NORs median among 19 benign tumors was 1.484 (SD +/- 0.265) and of 14 malignant tumors was 1.436 (SD +/- 0.414); the NORs areas were 2.6584 (SD +/- 1.0653) and 2.3643 (SD +/- 0.6320), respectively.
  • CONCLUSION: Our results showed that AgNOR evaluation was not a significant parameter to discriminate between malignant and benign thyroid lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927638.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Ferru A, Denis S, Guilhot J, Gibelin H, Tourani JM, Kraimps JL, Larsen CJ, Karayan-Tapon L: Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours. Eur J Surg Oncol; 2006 Mar;32(2):228-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Differential expression of the TAp73, DeltaTAp73 transcripts was measured in a panel of 60 thyroid malignancies by quantitative RT-PCR.
  • RESULTS: By comparison to normal thyroid tissue surrounding the tumours, we observed significant downregulation of TP73 transcripts in adenomas and in differentiated carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular / chemistry. Adenoma, Oxyphilic / chemistry. Carcinoma, Papillary / chemistry. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Thyroid Neoplasms / chemistry. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290057.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


53. Cupisti K, Raffel A, Ramp U, Wolf A, Donner A, Krausch M, Eisenberger CF, Knoefel WT: Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J; 2005 Apr;52(2):281-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter.
  • We report the case of a 52-year-old man with the history of two previous thyroid operations for benign goiters, who developed a recurrent goiter.
  • In the pathohistological examination the specimen showed a 5 cm follicular carcinoma and a 0.3 cm papillary microcarcinoma in the right lobe as well as a 1.5 cm medullary carcinoma in the left lobe.
  • This work represented possible long term exposure to inhalative carcinogenous toxins like hydrazine, which caused thyroid parafollicular cell adenomas in an animal model.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology. Goiter / complications. Neoplasms, Multiple Primary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863962.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Yang GC, Liebeskind D, Messina AV: Diagnostic accuracy of follicular variant of papillary thyroid carcinoma in fine-needle aspirates processed by ultrafast Papanicolaou stain: histologic follow-up of 125 cases. Cancer; 2006 Jun 25;108(3):174-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of follicular variant of papillary thyroid carcinoma in fine-needle aspirates processed by ultrafast Papanicolaou stain: histologic follow-up of 125 cases.
  • BACKGROUND: Detection of follicular variant (FV) of papillary carcinoma (PC) of the thyroid is considered difficult in cytology.
  • Of the 107 aspirates with diffuse "grape-like" watery clear nuclei, histologic follow-up showed 94 PCs, 8 follicular adenomas containing atypical nuclei, and 5 nonneoplastic lesions.
  • Of the 18 aspirates with focal clear nuclei, histologic follow-up showed 6 PCs, 8 follicular adenomas, and 4 nonneoplastic nodules.
  • The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy in the detection of PC were 93.6%, 94.9%, 93.6%, 94.9%, and 94.3%, respectively, when follicular adenomas containing atypical nuclei were counted as encapsulated FVPC; and 92.6%, 85.6%, 80%, 94.9%, and 88.3%, respectively, when follicular adenomas containing atypical nuclei were counted as benign.
  • [MeSH-major] Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541452.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Yang AD, Melstrom LG, Bentrem DJ, Ujiki MB, Wayne JD, Strouch M, Bell RH, Rao SM, Talamonti MS: Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience. Surgery; 2007 Oct;142(4):529-34; discussion 534-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience.
  • PURPOSE: To evaluate the experience with pancreatectomy for intraductal papillary mucinous neoplasm (IPMN) at a single academic institution.
  • Nine patients had adenomas, 14 had borderline neoplasms, 10 had carcinoma in situ, and 9 had invasive carcinoma.
  • The 5-year disease-specific survival for patients with benign lesions was 100%, and 61% for patients with malignant lesions (P = .02).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / statistics & numerical data. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950345.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M: Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol; 2008 Aug;21(8):1044-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighty-one surgically resected pancreatic lesions, including 35 pancreatic ductal adenocarcinoma, 26 intraductal papillary-mucinous neoplasms, 11 mucinous cystic neoplasms and 9 chronic pancreatitis, were studied.
  • Intraductal papillary-mucinous neoplasms were classified into four groups on the basis of the histological grade, namely, adenoma, non-invasive adenocarcinoma, adenocarcinoma with microscopical invasion and with macroscopically evident invasion.
  • In intraductal papillary-mucinous neoplasm, periostin deposition in the periductal stroma increased in frequency and intensity in adenocarcinoma compared with adenomas (P=0.014).
  • Furthermore, our results showed that a higher frequency of periostin deposition was correlated with a higher frequency of 'intestinal phenotype' of proliferating epithelium (P=0.036) and laminin-5gamma2 chain expression (P<0.001) in intraductal papillary-mucinous neoplasm, the latter of which is frequently expressed in invasive carcinoma.
  • This is the first report to describe the periostin immunohistochemistry in intraductal papillary mucinous neoplasm of the pancreas.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487994.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DNA, Neoplasm; 0 / POSTN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


57. D'Agostini F, Balansky R, Steele VE, Ganchev G, Pesce C, De Flora S: Preneoplastic and neoplastic lesions in the lung, liver and urinary tract of mice exposed to environmental cigarette smoke and UV light since birth. Int J Cancer; 2008 Dec 1;123(11):2497-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When the experiment was stopped, after 330 days, the number of lung adenomas was higher in ECS-exposed mice as compared to sham-exposed mice, but such increase was statistically significant only in mice co-exposed to smoke and halogen light mimicking solar irradiation.
  • In contrast, induction by ECS of alterations in the urinary tract, such as microadenomas and adenomas in renal pelvis and kidney, papillary hyperplasia of urothelium, and urinary bladder papillomas, were unrelated to the exposure time after birth.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Feb 5;23(5):1166-76 [14647414.001]
  • [Cites] Toxicol Lett. 2004 Mar 14;148(1-2):1-9 [15019083.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438 [15285078.001]
  • [Cites] Toxicol Sci. 2004 Sep;81(1):26-34 [15159525.001]
  • [Cites] Toxicol Sci. 2004 Oct;81(2):280-92 [15213336.001]
  • [Cites] FASEB J. 2004 Oct;18(13):1559-61 [15289447.001]
  • [Cites] Cancer Lett. 1988 Dec 15;43(3):173-7 [3203336.001]
  • [Cites] Carcinogenesis. 1989 Jun;10(6):1089-97 [2655963.001]
  • [Cites] J Cancer Res Clin Oncol. 1990;116(6):604-8 [2254379.001]
  • [Cites] Carcinogenesis. 1991 Aug;12(8):1409-15 [1860162.001]
  • [Cites] J Toxicol Sci. 1991 Feb;16 Suppl 1:53-62 [1920544.001]
  • [Cites] Carcinogenesis. 1993 Aug;14(8):1545-8 [8353839.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):839-45 [7645968.001]
  • [Cites] Carcinogenesis. 1997 Mar;18(3):575-86 [9067559.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2035-42 [9395199.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210 [10413421.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1999;71 Pt 1:1-315 [10507919.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):3-18 [15765916.001]
  • [Cites] Inhal Toxicol. 2005 May;17(6):263-76 [15814487.001]
  • [Cites] Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:171-81 [16092725.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):1999-2009 [15944214.001]
  • [Cites] Mutagenesis. 2006 Jan;21(1):61-6 [16399846.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1001-6 [17283132.001]
  • [Cites] Mutat Res. 2008 Sep 26;644(1-2):38-42 [18640134.001]
  • [Cites] Mutat Res. 2008 Jul-Aug;659(1-2):137-46 [18155953.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2236-43 [17522065.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):607-15 [11179494.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):793-800 [12591728.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:237-52 [12628522.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1525-32 [12844483.001]
  • [Cites] Mutat Res. 2003 Nov;544(2-3):441-9 [14644347.001]
  • (PMID = 18770867.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 CN053301; United States / NCI NIH HHS / CA / N01CN53301; United States / NCI NIH HHS / CN / N01 CN053301; United States / NCI NIH HHS / CN / N01-CN53301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  • [Other-IDs] NLM/ NIHMS70896; NLM/ PMC2583251
  •  go-up   go-down


58. Sibio S, Borrini F, Sammartino P, Accarpio F, Biacchi D, Caprio G, Iafrate F, Baccheschi AM, Cornali T, Di Giorgio A: Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features. Endocr Pathol; 2010 Sep;21(3):199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominant Brenner tumor combined with struma ovarii containing a papillary microcarcinoma associated with benign peritoneal strumosis: report of a case and histologic features.
  • Brenner tumor and struma ovarii, two uncommon ovarian tumors arising alone or together with dermoid cysts or adenomas, are both rare entities.
  • The mass consisted predominantly of a Brenner tumor associated with struma ovarii containing a single small island of thyroid tissue that had undergone malignant transformation into a well-differentiated papillary carcinoma and also normal thyroid tissue that had spread to the peritoneum.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Papillary / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Struma Ovarii / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):447-51 [10366477.001]
  • [Cites] Eur J Gynaecol Oncol. 1994;15(2):138-41 [8005144.001]
  • [Cites] Arch Surg. 1946 Dec;53(6):603-26 [20279410.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):793-7 [15482570.001]
  • [Cites] Obstet Gynecol. 1976 Nov;48(5):579-89 [185553.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(1):109-10 [15755015.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):835-9 [15350384.001]
  • [Cites] Eur J Gynaecol Oncol. 1980 May;1(2):108-11 [7333303.001]
  • [Cites] Cancer. 1971 Jun;27(6):1482-8 [4325989.001]
  • [Cites] Obstet Gynecol. 1963 Mar;21:384-6 [13936652.001]
  • [Cites] Thyroid. 2009 Mar;19(3):305-8 [19265502.001]
  • [Cites] Obstet Gynecol. 1968 Jun;31(6):779-84 [5760238.001]
  • [Cites] Int J Gynecol Pathol. 1993 Oct;12(4):333-43 [8253550.001]
  • [Cites] Am J Obstet Gynecol. 1950 Dec;60(6):1315-23 [14789894.001]
  • [Cites] Cancer. 1976 Nov;38(5):1997-2001 [991113.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):213-22 [18317221.001]
  • [Cites] Ginecol Obstet Mex. 1999 Apr;67:153-7 [10363413.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):74-7 [11781528.001]
  • [Cites] Eur J Nucl Med. 1996 Jan;23 (1):91-4 [8586108.001]
  • [Cites] Cancer. 1971 Mar;27(3):687-93 [5549500.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):575-7 [11520159.001]
  • (PMID = 20532676.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Wiersinga WM: Management of thyroid nodules in children and adolescents. Hormones (Athens); 2007 Jul-Sep;6(3):194-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant nodules are predominantly papillary cancers; benign nodules are mostly solid colloid nodules/adenomas, but can be cystic or due lymphocytic thyroiditis.
  • Thyroid ultrasound is useful, especially in guidance of FNAC for optimal results, but presently should not be used for final decisions on the benign or malignant nature of the nodule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724003.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  • [Number-of-references] 32
  •  go-up   go-down


60. Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg; 2009 Aug;13(8):1510-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
  • BACKGROUND: Mutations of KRAS are known to occur in periampullary and ampullary adenomas and carcinomas.
  • While oncogenic BRAF contributes to the tumorigenesis of both pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasms/carcinomas (IPMN/IPMC), PIK3CA mutations were only detected in IPMN/IPMC.
  • This study aimed to elucidate possible roles of BRAF and PIK3CA in the development of ampullary and periampullary adenomas and carcinomas.
  • METHODS: Mutations of BRAF, NRAS, HRAS, KRAS, and PIK3CA were evaluated in seven adenomas, seven adenomas with carcinoma in situ, and 21 adenocarcinomas of the periampullary duodenal region and the ampulla of Vater.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2756-60 [7796400.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1875-8 [7753564.001]
  • [Cites] J Clin Pathol. 1996 Jun;49(6):460-4 [8763258.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):91-5 [9247130.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):129-33 [9815548.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Cancer Biol Ther. 2004 Aug;3(8):772-5 [15254419.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1477-80 [15608678.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1441-6 [16533766.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):163-70 [16478646.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):34-46 [10579909.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):543-55 [11459270.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:615-75 [11687500.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7420-5 [12032298.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7001-3 [12460919.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1983-93 [12612072.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):272-8 [12640108.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):169-73 [12969789.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1255-60 [14507635.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):305-10 [3972407.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • (PMID = 19440799.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701; United States / NCI NIH HHS / CA / CA127701-01A2; United States / NCI NIH HHS / CA / R01CA109525; United States / NCI NIH HHS / CA / R01 CA109525; United States / NCI NIH HHS / CA / CA109525-05; United States / NCI NIH HHS / CA / R21 CA127701-01A2; United States / NCI NIH HHS / CA / R21CA127701
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS164917; NLM/ PMC3915027
  •  go-up   go-down


61. Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, Filetti S, Russo D, Damante G: Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid; 2009 Mar;19(3):247-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
  • The objective of this study was to evaluate PHB expression in normal thyroid tissues, thyroid follicular adenomas (FAs), and papillary thyroid carcinomas (PTCs).
  • METHODS: PHB expression was analyzed by immunohistochemistry, Western blot, and quantitative reverse transcription polymerase chain reaction (RT-PCR).
  • PHB mRNA and protein overexpression, as assessed by quantitative RT-PCR and Western blot, was noted only in PTCs bearing the BRAF(V600E) mutation.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Mutation / physiology. Proto-Oncogene Proteins B-raf / genetics. Repressor Proteins / biosynthesis. Repressor Proteins / genetics. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adult. Blotting, Western. Cell Line. DNA Primers. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Thyrotropin / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207009.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / prohibitin; 9002-71-5 / Thyrotropin; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


62. Handra-Luca A, Fléjou JF, Rufat P, Corcos O, Belghiti J, Ruszniewski P, Degott C, Bedossa P, Couvelard A: Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology; 2006 Jun;48(7):813-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.
  • AIMS: To examine cytokeratin, epithelial glycoprotein (mucin) and glycoprotein CD10 expression in benign mucinous cystdenomas (MCAs) in comparison with intraductal papillary mucinous adenomas (IPMAs).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology


63. Ball E, Bond J, Franc B, Demicco C, Wynford-Thomas D: An immunohistochemical study of p16(INK4a) expression in multistep thyroid tumourigenesis. Eur J Cancer; 2007 Jan;43(1):194-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal human thyroid follicular epithelial cells exhibit a very low proliferative rate which in vitro is dramatically increased by RAS oncogene activation, resulting in clones displaying a phenotype consistent with that of a ras-induced follicular adenoma in vivo.
  • We therefore hypothesised that p16 expression would also increase in vivo in follicular adenomas, and further that escape from growth control in follicular cancers would be accompanied by loss of p16 expression.
  • Whereas the majority of normal thyroids showed no immunostaining, p16 protein was readily detectable in follicular adenomas.
  • Unexpectedly, however, p16 expression was also observed in follicular and papillary carcinomas.
  • [MeSH-major] Adenoma / metabolism. Cell Transformation, Neoplastic / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17046239.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


64. Knezević-Obad A, Tomić-Brzac H, Zarković K, Dodig D, Stromar IK: Diagnostic pitfalls in parathyroid gland cytology. Coll Antropol; 2010 Mar;34(1):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to establish possibilities of using cytology in the diagnosis of parathyroid gland adenoma.
  • The adenoma was diagnosed via morphological characteristics in 71 out of 288 punctates that were proven adequate for cytological analysis.
  • Increased PTH levels were later on established in all diagnosed adenomas.
  • All patients with cytology-based diagnosis of parathyroid gland adenoma were sent to surgery, and the cytological diagnosis was confirmed by pathohistology.
  • In three cases, the parathyroid gland adenoma was established by pathohistology, although in these cases the cytological diagnosis was negative.
  • The cytological diagnosis of parathyroid gland adenoma can be considered reliable in 96% of cases, provided that the echosonographic structure and localisation of the punctured node is noted, and assuming that material adequate for cytological analysis is obtained by FNAB.
  • Possible pitfalls are oncocytic types of parathyroid adenoma, intranuclear inclusions and papillary formation of epithelial cells, and cystic degeneration of nodules.
  • [MeSH-major] Adenoma / pathology. Biopsy, Fine-Needle / standards. Parathyroid Glands / pathology. Parathyroid Neoplasms / pathology

  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432729.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / May-Grunwald Giemsa; 0 / Parathyroid Hormone; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


65. Jones TD, Eble JN, Wang M, MacLennan GT, Delahunt B, Brunelli M, Martignoni G, Lopez-Beltran A, Bonsib SM, Ulbright TM, Zhang S, Nigro K, Cheng L: Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res; 2005 Oct 15;11(20):7226-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
  • PURPOSE: In patients with papillary renal cell carcinoma, it is not uncommon to find two or more anatomically distinct and histologically similar tumors at radical nephrectomy.
  • Whether these multiple papillary lesions result from intrarenal metastasis or arise independently is unknown.
  • However, similar clonality assays for multifocal papillary renal cell neoplasia have not been done.
  • All patients had multiple separate papillary lesions (ranging from 2 to 5).
  • Eighteen patients had multiple papillary renal cell carcinomas.
  • Seven had one or more papillary renal cell carcinomas with coexisting papillary adenomas.
  • X-chromosome inactivation analyses were done on the papillary kidney tumors from three female patients.
  • RESULTS: Twenty of 21 (95%) cases showed allelic loss in one or more of the papillary lesions in at least one of the six polymorphic markers analyzed.
  • A concordant pattern of nonrandom X-chromosome inactivation in the coexisting multiple papillary lesions was seen in two of three female patients.
  • CONCLUSION: Our data suggest that, unlike multifocal clear cell renal cell carcinomas, the multiple tumors in patients with papillary renal cell carcinoma arise independently.
  • Thus, intrarenal metastasis does not seem to play an important role in the spread of papillary renal cell carcinoma, a finding that has surgical, therapeutic, and prognostic implications.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Loss of Heterozygosity

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 Oct 15;11(20):7206-8 [16243789.001]
  • (PMID = 16243792.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Tavangar SM, Monajemzadeh M, Larijani B, Haghpanah V: Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Med J; 2007 Aug;48(8):744-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Incidence of oestrogen receptor positive cases were 24 percent (31/130) for nodular goitres, 22 percent (8/37) for follicular adenomas, 11 percent (2/18) for follicular carcinomas, 31 percent (37/119) for papillary carcinomas, zero percent (0/35) for medullary carcinomas and zero percent (0/12) for undifferentiated carcinomas.
  • CONCLUSION: The relatively high proportion of oestrogen receptor positivity in goitres, follicular adenomas and papillary carcinomas, compared with its reactivity in other thyroid neoplasms, and contrasted against normal thyroid tissue, suggests that the incidence of oestrogen receptor reactivity tends to increase with better differentiation of thyroid lesions.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Adult. Carcinoma, Papillary / metabolism. Female. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657383.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


67. Keramidas EG, Miller G, Revelos K, Kitsanta P, Page RE: Aggressive digital papillary adenoma-adenocarcinoma. Scand J Plast Reconstr Surg Hand Surg; 2006;40(3):189-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenoma-adenocarcinoma.
  • Aggressive digital papillary adenocarcinoma and aggressive digital papillary adenoma are rare tumours of the sweat glands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687341.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Oikonomou E, Barreto DC, Soares B, De Marco L, Buchfelder M, Adams EF: Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. J Neurooncol; 2005 Jul;73(3):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin mutations in craniopharyngiomas and pituitary adenomas.
  • Craniopharyngiomas and pituitary adenomas are both tumors of the hypothalamic and pituitary region, respectively that are frequently associated with endocrine defects either because of direct involvement of hormone producing cells (most pituitary tumors) or because of secondary defects due to disturbance of hypothalamic function (some pituitary tumors and craniopharyngiomas).
  • Some studies suggest that mutant beta-catenin gene cells in craniopharyngiomas and pituitary adenomas contribute to their tumorigenesis.
  • None of the 22 pituitary adenomas and the eight papillary craniopharyngiomas analyzed presented any sequence alterations.
  • [MeSH-major] Adenoma / genetics. Craniopharyngioma / genetics. Cytoskeletal Proteins / genetics. Pituitary Neoplasms / genetics. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Endocrinologie. 1990 Apr-Jun;28(2):67-72 [2293330.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):42-8 [11148558.001]
  • [Cites] Genes Dev. 2000 Aug 1;14 (15):1837-51 [10921899.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):225-9 [12824913.001]
  • [Cites] Bioessays. 1989 Oct;11(4):88-91 [2695079.001]
  • [Cites] Semin Diagn Pathol. 1986 Feb;3(1):69-82 [3039632.001]
  • [Cites] Science. 1991 Mar 22;251(5000):1451-5 [2006419.001]
  • [Cites] Development. 1998 Nov;125(21):4225-34 [9753677.001]
  • [Cites] J Embryol Exp Morphol. 1975 Oct;34(2):311-25 [1194833.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):243-8 [10679188.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):543-8 [11472567.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):725-51 [11787845.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1357-65 [12481018.001]
  • (PMID = 15980970.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


69. Castro P, Roque L, Magalhães J, Sobrinho-Simões M: A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol; 2005 Jul;13(3):235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation.
  • The occurrence of the PAX8-PPARgamma fusion gene is thought to be restricted to follicular tumors (adenomas and carcinomas) of the thyroid (FTA and FTC).
  • Using interphase fluorescent in situ hybridization (FISH), together with recombinant tissue-type polymerase chain reaction (RT-PCR) and immunohistochemistry, we detected the PAX8-PPARgamma translocation in 4 of 8 cases of the follicular variant of papillary thyroid carcinoma (FVPTC) exclusively or almost exclusively (>95%) composed of follicles.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086077.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / PAX8 Transcription Factor; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Trans-Activators
  •  go-up   go-down


70. Ferlicot S, Allory Y, Compérat E, Mege-Lechevalier F, Dimet S, Sibony M, Couturier J, Vieillefond A: Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature. Virchows Arch; 2005 Dec;447(6):978-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Until this entity had been defined, pathologists used to classify these tumors as variants of solid papillary carcinomas with compressed and elongated papillae, metanephric adenomas, and sarcomatoid carcinomas.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathologe. 2003 Oct;24(6):453-9 [14605851.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):954-60 [11844069.001]
  • [Cites] Pathol Int. 1998 May;48(5):416-20 [9704350.001]
  • [Cites] Hum Pathol. 2001 May;32(5):506-12 [11381369.001]
  • [Cites] Histopathology. 2005 Aug;47(2):218-9 [16045786.001]
  • [Cites] Pathology. 2003 Dec;35(6):499-504 [14660100.001]
  • [Cites] Hum Pathol. 2002 May;33(5):574-5; author reply 575-6 [12094388.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1162-71 [12429795.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):164-72 [12407697.001]
  • [Cites] Histopathology. 2002 Dec;41(6):549-55 [12460208.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):69-76 [14707866.001]
  • (PMID = 16231179.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


71. Briese J, Cheng S, Ezzat S, Liu W, Winer D, Wagener C, Bamberger AM, Asa SL: Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res; 2010 May;30(5):1681-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some thyroid adenomas were weakly OPN positive whereas many carcinomas were strongly positive.
  • In contrast to CEACAM1, which was preferentially expressed in metastatic papillary carcinomas, no associations were found between OPN expression and patient age, gender and tumour size.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592361.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 106441-73-0 / Osteopontin
  •  go-up   go-down


72. Nygaard B, Frisch T, Kiss K: [Thyroid papillary cancer using TPO staining]. Ugeskr Laeger; 2008 Apr 28;170(18):1571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid papillary cancer using TPO staining].
  • Immunostaining for TPO (MoAb47) has been used to predict the risk of thyroid cancer in thyroid adenomas without uptake in thyroid 99m pertechnetate scintigraphy.
  • This case describes a 16-year-old girl with thyroid papillary cancer staining 95% positive using TPO staining.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Papillary / diagnosis. Iodide Peroxidase / analysis. Staining and Labeling / methods. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454932.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


73. El Demellawy D, Nasr A, Alowami S: Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol; 2008;3:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.
  • Papillary carcinoma of the thyroid (PTC) is the commonest thyroid cancer.
  • The neoplastic cases included 75 carcinomas (72 papillary, 2 follicular, 1 Hurthle cell) and 35 adenomas (32 follicular and 3 Hurthle cell).

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] J Cell Sci. 2000 May;113 ( Pt 10):1661-70 [10769197.001]
  • [Cites] Nat Cell Biol. 2001 Jul;3(7):650-7 [11433297.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):16-8 [11791591.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] Pathol Res Pract. 2002;198(7):449-54 [12234063.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] Int J Immunopathol Pharmacol. 1999 Jan-Apr;12(1):23-30 [12793959.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):279-87 [15505528.001]
  • [Cites] Mol Biol Cell. 2005 Sep;16(9):4280-93 [16000376.001]
  • [Cites] Gene. 1990 Nov 15;95(2):203-13 [1701153.001]
  • [Cites] J Pathol. 2007 Aug;212(4):411-9 [17573672.001]
  • [Cites] J Exp Med. 1989 Jun 1;169(6):2233-8 [2471777.001]
  • [Cites] Science. 1988 Apr 1;240(4848):53-7 [3281256.001]
  • [Cites] Am J Surg Pathol. 1977 Jun;1(2):123-30 [602974.001]
  • [Cites] Ciba Found Symp. 1995;189:124-36; discussion 136-41, 174-6 [7587628.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6B):4111-7 [9428343.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • (PMID = 18254952.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2267445
  •  go-up   go-down


74. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M: Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene; 2006 Aug 31;25(39):5467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and approximately 40% developed invasive follicular carcinomas, in some cases with a mixed papillary/follicular morphology.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / pathology. Amino Acid Substitution. Animals. Cell Differentiation. Humans. Mice. Mice, Transgenic. Neoplasm Invasiveness


75. Zheng BA, Deng GL, Dong QJ, Zhao ZS, Deng YC: [Relationship between E-CD and Snail expressions and tumor invasion, metastasis and prognosis in colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Feb;32(2):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunohistochemical staining (EnVision) was used to detect the E-CD and Snail expressions in 30 normal colorectal mucosa, 30 colorectal adenoma and 142 colorectal cancer tissues.
  • RESULTS: E-CD in the normal colorectal mucosa was strongly positive expressed (90.0%), significantly higher than that in colorectal adenomas (63.3%) and colorectal cancer tissues (41.5%).
  • The positive expression rate of Snail in colorectal cancer tissues (52.1%) was significantly higher than that in normal colorectal mucosa (6.7%) and colorectal adenomas (26.7%, P < 0.05).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / metabolism. Adolescent. Adult. Aged. Female. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403241.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


76. Laco J, Ryska A: [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern]. Cesk Patol; 2006 Jul;42(3):120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of 139 cases - 87 follicular adenomas (FAs), 26 follicular carcinomas (FCs), and 26 cases of the follicular variant of papillary carcinoma (FVPC) was studied.
  • [MeSH-minor] Adenoma / chemistry. Adenoma / diagnosis. Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary, Follicular / chemistry. Carcinoma, Papillary, Follicular / diagnosis. Diagnosis, Differential. Female. Galectin 3 / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neural Cell Adhesion Molecule L1 / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955558.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Galectin 3; 0 / Neural Cell Adhesion Molecule L1; 68238-35-7 / Keratins
  •  go-up   go-down


77. Bohnacker S, Soehendra N, Maguchi H, Chung JB, Howell DA: Endoscopic resection of benign tumors of the papilla of vater. Endoscopy; 2006 May;38(5):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of benign tumors of the papilla of vater.
  • Most benign papillary tumors are adenomas which can potentially undergo the adenoma-carcinoma-sequence making complete removal mandatory for curative therapy.
  • For benign looking papillary tumors, endoscopic papillectomy serves as a diagnostic tool and should be considered as first line procedure regardless of age.
  • The following article details the approach to patients with benign papillary tumor and the technique of endoscopic papillectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767591.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


78. Böör A, Jurkovic I, Havierová Z, Kocan P: Prolonged treatment of chronic renal insufficiency, acquired cystic kidney disease, simultaneous precancerous lesions and multiple tumors of left kidney. Cesk Patol; 2010 Oct;46(4):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy revealed acquired cystic kidney disease associated with multiple precancerous lesions, several small papillary adenomas and a multifocal renal cell carcinoma with conventional and papillary structures with admixture of small foci of highly cellular sarcomatoid features.
  • PRINCIPAL CONCLUSIONS: This case illustrates the association of chronic renal insufficiency, uremic oxalosis, long-term hemodialysis, acquired cystic kidney disease and development of variable precursor intratubular and intracystic lesions progressing to several papillary adenomas and multifocal renal cell carcinomas with variegated microscopic structures in one kidney.


79. Mazzoni A: The petro-occipital trans-sigmoid approach for lesions of the jugular foramen. Skull Base; 2009 Jan;19(1):48-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective review was conducted of 61 patients with jugular fossa tumors that included lower cranial nerve schwannomas, paragangliomas, meningiomas, chordomas, cholesteatomas, and other benign or low-grade malignant tumors.
  • Good outcomes were achieved for schwannomas, meningiomas, chondrosarcomas, and papillary adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skull Base Surg. 1995;5(3):157-67 [17170942.001]
  • [Cites] Arch Otolaryngol. 1964 Mar;79:219-24 [14090421.001]
  • [Cites] J Laryngol Otol. 1952 Jul;66(7):302-14 [14938784.001]
  • [Cites] Arch Otolaryngol. 1971 Mar;93(3):227-31 [5100624.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1982 Sep-Oct;91(5 Pt 1):474-9 [6291440.001]
  • [Cites] Laryngoscope. 1974 Nov;84(11):2006-32 [4373628.001]
  • [Cites] J Neurosurg. 1971 Jul;35(1):59-64 [4328295.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 May;106(5):370-9 [9153100.001]
  • (PMID = 19568342.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2637570
  • [Keywords] NOTNLM ; Jugular foramen / petro-occipital trans-sigmoid approach / surgical procedures / tumors of jugular foramen
  •  go-up   go-down


80. Lee HM, Baek SK, Kwon SY, Jung KY, Chae SW, Hwang SJ, Woo JS, Lee JY: Cyclooxygenase 1 and 2 expressions in the human thyroid gland. Eur Arch Otorhinolaryngol; 2006 Mar;263(3):199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the expression of COX-1 and COX-2 in normal thyroid tissue, follicular adenoma and well-differentiated thyroid carcinomas and evaluated the difference in COX-1 and COX-2 expression.
  • Ten normal thyroid tissues, ten follicular adenomas, ten papillary carcinomas and ten follicular carcinomas were analyzed by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for expression of COX-1 and COX-2 mRNA.
  • Expression of COX-1 mRNA in the normal thyroid tissues, follicular adenomas and both well-differentiated carcinomas was similar and weak.
  • However, COX-2 mRNA was strongly expressed in the well-differentiated carcinomas compared to those of normal thyroid tissue and follicular adenoma.
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor. Biopsy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Humans. Immunohistochemistry. RNA, Messenger. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3028-31 [9679967.001]
  • [Cites] Prostaglandins. 1996 Jan;51(1):81-5 [8900446.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21455-60 [9261162.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):331-40 [12665651.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Mar;280(3):C701-8 [11171589.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Endocrinol Metab Clin North Am. 1997 Mar;26(1):189-218 [9074859.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):589-96 [10931458.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10911-5 [10196169.001]
  • [Cites] J Biol Chem. 1996 Dec 27;271(52):33157-60 [8969167.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Endocr Pathol. 2004 Summer;15(2):107-16 [15299197.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):362-6 [9443418.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • (PMID = 16362262.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


81. Munshi AG, Hassan MA: Common bile duct adenoma: case report and brief review of literature. Surg Laparosc Endosc Percutan Tech; 2010 Dec;20(6):e193-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common bile duct adenoma: case report and brief review of literature.
  • Papillary adenomas of the common bile duct are a rare entity with few published case reports and limited knowledge on its natural progression.
  • We report here a case of common bile duct papillary adenoma in a 69-year-old female who presented with symptoms of common bile duct obstruction.
  • She was treated with local endoscopic excision of the mass that has benign features.
  • A brief review of literature is discussed with a proposed treatment plan for follow-up with surveillance endoscopy and ultrasonography as opposed to the radical resection for benign findings on pathology.
  • [MeSH-major] Adenoma / surgery. Common Bile Duct Neoplasms / surgery

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for bile duct adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150400.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


82. Szponar A, Yusenko MV, Kovacs G: High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes. Histopathology; 2010 Jan;56(2):212-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes.
  • AIMS: Previous karyotyping and fluorescence in situ hybridization analysis of metanephric adenomas (MAs) has yielded controversial data.
  • METHODS AND RESULTS: DNA extracted from paraffin blocks of six metanephric adenomas was hybridized onto Agilent oligoarrays with approximately 43,000 in situ synthesized 60-mer oligonucleotide probes that span coding and non-coding sequences with an average spatial resolution of approximately 35 kb.
  • None of the metanephric adenomas showed DNA copy number changes.
  • CONCLUSIONS: Our high-resolution oligoarray analysis indicates that metanephric adenomas lack DNA copy number alterations.
  • This finding may help to differentiate between metanephric adenomas from Wilms' tumour and papillary renal cell adenoma with overlapping phenotype.
  • [MeSH-major] Adenoma / genetics. DNA Copy Number Variations. Kidney Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102400.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Chang YJ, Mittal V, Remine S, Manyam H, Sabir M, Richardson T, Young S: Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg; 2006 May;72(5):419-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 168 patients who underwent parathyroid excision, 14 (8.3%) had hyperplasia of the parathyroid, 121 (72%) had benign adenoma, 25 (14.8%) had other benign lesions, and 8 (4.7%) patients had primary carcinoma of the parathyroid confirmed by pathology.
  • Our mean serum calcium level was 11.57 mg/dL, which was lower than the mean level (12 mg/dL) for benign hyperparathyroidism.
  • Seven of eight patients (87.5%) had frank signs of invasion together with other histological features, and two patients had associated papillary carcinoma of the thyroid.
  • On the other hand, 17 patients with benign histology had tumors greater than 3 cm, and an additional 18 had palpable masses on physical examination.
  • The patients with diagnosis of parathyroid carcinoma, their kindred, and those with large adenomas may benefit from genetic screening for HRTP2 gene mutations in search of early detection of tumors suspicious for malignancy.
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / surgery. Aged, 80 and over. Calcium / blood. Female. Humans. Hyperparathyroidism / etiology. Male. Middle Aged. Mitosis. Neoplasm Invasiveness. Parathyroidectomy

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719197.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  •  go-up   go-down


84. Went PT, Sauter G, Oberholzer M, Bubendorf L: Abundant expression of AMACR in many distinct tumour types. Pathology; 2006 Oct;38(5):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Microarray analysis revealed that tumours with prominent AMACR expression included adenocarcinomas of the prostate (72%), hepatocellular carcinomas (77%), papillary renal cell carcinomas (70%), and colorectal adenocarcinomas (71%).
  • AMACR expression was equally frequent in colorectal adenomas and carcinomas.
  • In the thyroid, AMACR expression was found in 42% of the follicular carcinomas but in only 16% of follicular adenomas.
  • However, a more detailed analysis on a thyroid tissue microarray did not confirm a significant difference of AMACR expression in follicular adenoma and carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008281.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


85. Skubis-Zegadło J, Nikodemska A, Przytuła E, Mikula M, Bardadin K, Ostrowski J, Wenzel BE, Czarnocka B: Expression of pendrin in benign and malignant human thyroid tissues. Br J Cancer; 2005 Jul 11;93(1):144-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of pendrin in benign and malignant human thyroid tissues.
  • Pendrin expression has been studied in various thyroid neoplasms by means of immunohistochemistry (IHC), Western blot and RT-quantitative real-time PCR.
  • In follicular adenomas, pendrin was detected in cell membranes and cytoplasm simultaneously in 10 out of 15 cases.
  • Pendrin protein was detected in 73.3 and 76.7% of the follicular (FTC) and papillary (PTC) thyroid carcinomas, respectively, where pendrin was solely localised inside the cytoplasm.
  • Focal reactivity was detected in one follicular- and three papillary carcinomas, whereas pendrin protein was absent in three of 15 FTC and four of 30 PTC; mRNA of pendrin was detected in 92.4% of thyroid tumours.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2000 Feb;141(2):839-45 [10650967.001]
  • [Cites] J Med Genet. 1999 Aug;36(8):595-8 [10465108.001]
  • [Cites] Eur J Endocrinol. 2001 Mar;144(3):297-302 [11248751.001]
  • [Cites] Eur J Endocrinol. 2001 Aug;145(2):129-35 [11454507.001]
  • [Cites] Thyroid. 2001 Sep;11(9):825-30 [11575851.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1700-7 [11932304.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1778-84 [11932316.001]
  • [Cites] Biotechniques. 2002 Jun;32(6):1372-4, 1376, 1378-9 [12074169.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3356-61 [12107249.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3500-3 [12107270.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1178-85 [12142370.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):167-73 [12533525.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):48-77 [12588808.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2312-5 [12727855.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4977-83 [14557483.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):13004-10 [14715652.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):C590-7 [1384345.001]
  • [Cites] Exp Clin Endocrinol. 1992;100(1-2):51-6 [1281780.001]
  • [Cites] Nature. 1996 Feb 1;379(6564):458-60 [8559252.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Sep 13;226(2):339-45 [8806637.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):411-22 [9398842.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):440-3 [10192399.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):2028-33 [10843192.001]
  • (PMID = 15942636.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / SLC26A4 protein, human
  • [Other-IDs] NLM/ PMC2361481
  •  go-up   go-down


86. Bai XJ, Yang M, Yu Q, Li N: [Renal papillary adenoma in transplant donor kidney: report of a case]. Zhonghua Bing Li Xue Za Zhi; 2009 May;38(5):353-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal papillary adenoma in transplant donor kidney: report of a case].
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms / pathology. Kidney Transplantation. Living Donors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575887.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Keratin-7; 0 / Mucin-1
  •  go-up   go-down


87. Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E: Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf); 2006 Jan;64(1):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
  • OBJECTIVES: The genes RET and RAS, and more recently BRAF, have been shown to be frequently mutated in human papillary thyroid carcinomas (PTC).
  • DESIGN AND PATIENTS: Thyroid tumours removed from 51 subjects were analysed, including 43 PTC and 8 non-PTC tumours [3 follicular adenomas (FA), 4 follicular carcinomas (FTC) and 1 anaplastic carcinoma (AC)].
  • [MeSH-major] Carcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402937.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


88. Hu MJ, Xu HD, Zhou R, Li XF, Zhang HY: [Loss of heterozygosity on chromosome 3p in thyroid tumors]. Zhonghua Bing Li Xue Za Zhi; 2008 May;37(5):305-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: LOH at 11 microsatellite loci was analyzed in 74 cases of thyroid tumors (including 20 follicular adenomas, 24 follicular thyroid carcinomas and 30 papillary thyroid carcinomas) by polymerase chain reaction and silver stain.
  • RESULTS: LOH on chromosome 3p was detected in 71% of follicular thyroid carcinoma (17/24), 30% of the papillary thyroid carcinoma (9/30) and 10% of the follicular adenoma (2/20) case.
  • 2-26.1) in papillary thyroid carcinoma.
  • CONCLUSIONS: LOH is more frequently identified in follicular thyroid carcinoma than in papillary thyroid carcinoma and follicular adenoma.
  • The 3 CDR on chromosome 3p may harbor tumor suppressor genes involved in the pathogenesis of follicular thyroid carcinoma and papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Chromosomes, Human, Pair 3 / genetics. Loss of Heterozygosity. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Chromosome Mapping. Chromosomes. Female. Genes, Tumor Suppressor / physiology. Heterozygote. Humans. Male. Microsatellite Repeats. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956647.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, Hamdi MM, Abdullah MS: Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Singapore Med J; 2008 Apr;49(4):333-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: It has been suggested that Galectin-3 (Gal-3) and Galectin-7 (Gal-7) are potential tumour markers for differentiating thyroid carcinoma from its benign counter part.
  • RESULTS: A total of 95 cases were collected, including 32 benign and 63 malignant thyroid lesions.
  • These contained 37 cases of papillary thyroid carcinoma, nine cases of papillary thyroid carcinoma follicular variant, 16 cases of follicular carcinoma, one case of anaplastic carcinoma, 14 cases of follicular adenomas and 18 cases of nodular goitre.
  • CONCLUSION: Our findings suggested that the IHC localisation of Gal-3 is a useful marker in conjunction with routine haematoylin and eosin staining in differentiating benign from malignant thyroid lesions, while there is no significant adjunct diagnostic value in Gal-7 for thyroid malignancy.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Adenoma / diagnosis. Adenoma / metabolism. Carcinoma, Papillary / diagnosis. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418527.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


90. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precancerous lesion with a well-described progression to carcinoma.
  • Phenotypic manifestations of Lynch syndrome in this patient included multiple adenomas and adenocarcinomas of the colon and also several other Lynch syndrome-associated cancers.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


91. Sofiadis A, Tani E, Foukakis T, Kjellman P, Skoog L, Höög A, Wallin G, Zedenius J, Larsson C: Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol; 2009 Aug;35(2):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the prognostic value of MIB-1 index was investigated for 183 of the patients with papillary thyroid cancer (PTC).
  • No significant difference in MIB-1 index was observed between thyroid adenomas and follicular carcinomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Cell Proliferation. Child. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578751.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  •  go-up   go-down


92. Goldfarb M, O'Neal P, Shih JL, Hartzband P, Connolly J, Hasselgren PO: Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism. Endocr Pract; 2009 Jul-Aug;15(5):463-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism.
  • OBJECTIVE: To describe a patient presenting with the rare constellation of synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma.
  • He was found to have a 3.4-cm parathyroid carcinoma on the left side and a 3.2-cm papillary carcinoma in the right thyroid lobe.
  • In addition, a 917-mg parathyroid adenoma was found on the right side.
  • To our knowledge, our patient is the first documented case with a parathyroid adenoma in addition to synchronous parathyroid and thyroid carcinomas.
  • The presence of concurrent parathyroid carcinoma and parathyroid adenoma can cause diagnostic confusion and should be considered in patients presenting with severe hyperparathyroidism.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ear Nose Throat J. 2002 Jun;81(6):395-8, 400-1 [12092283.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):255-64 [17559137.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Surg Oncol. 1999 Nov;8(3):155-65 [11113666.001]
  • [Cites] Mayo Clin Proc. 2002 Aug;77(8):866-9 [12173721.001]
  • [Cites] Am J Otolaryngol. 2002 Nov-Dec;23(6):382-5 [12430133.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):54-64 [12605367.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Cancer. 1973 Mar;31(3):600-5 [4693587.001]
  • [Cites] Nihon Gan Chiryo Gakkai Shi. 1979 Dec 20;14(7):1127-35 [541539.001]
  • [Cites] Br J Surg. 1988 Sep;75(9):873-4 [3179662.001]
  • [Cites] J Chin Med Assoc. 2005 Feb;68(2):87-91 [15759821.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1345-53 [16237743.001]
  • [Cites] Br J Surg. 2007 May;94(5):566-70 [17380564.001]
  • [Cites] J Endocrinol Invest. 2001 Jan;24(1):42-4 [11227731.001]
  • (PMID = 19491068.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] ENG
  • [Grant] United States / NINR NIH HHS / NR / NR008545-06; United States / NINR NIH HHS / NR / R56 NR008545; United States / NINR NIH HHS / NR / R56 NR008545-06
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217054; NLM/ PMC2917245
  •  go-up   go-down


93. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive report showed 45 benign (60%) and 30 malignant (40%) cases.
  • Benign cases included 29 goiters, 11 follicular adenomas, and 5 cases of thyroiditis.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • Tumor size of benign lesions was 3.43 ± 2.04 cm, and 4.67 ± 2.78 (p = 0.049) for malignant lesions.
  • Age was 46.95 ± 15.39 years for benign lesions and 48.67 ± 17.28 for malignant lesions (p = 0.66).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


94. Di Cristofaro J, Vasko V, Savchenko V, Cherenko S, Larin A, Ringel MD, Saji M, Marcy M, Henry JF, Carayon P, De Micco C: ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients. Endocr Relat Cancer; 2005 Mar;12(1):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In adenomas the prevalence of rearrangement was significantly higher in all Ukrainians than in French patients (P = 0.004).
  • [MeSH-major] Carcinoma, Papillary / etiology. Neoplasms, Radiation-Induced / etiology. Oncogene Proteins / genetics. Radioactive Hazard Release. Thyroid Neoplasms / etiology. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Radiation Emergencies.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788648.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NCOA4 protein, human; 0 / Nuclear Receptor Coactivators; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human
  •  go-up   go-down


95. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE: Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol; 2009 Dec 1;100(7):598-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinomas, NOS comprised 65% of all histological types.
  • Papillary carcinomas had a more favorable survival than other types; carcinomas arising in adenomas had a more favorable survival than adenocarcinomas not associated with adenomas.
  • CONCLUSIONS: Prognostic factors include histologic type, grade, stage, and coexisting adenomas.
  • Although certain histologic types exhibit morphologic differences, their pathogenesis appears to be similar.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697352.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement